Ocular Therapeutix
OCUL Mid CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Ocular Therapeutix en bref
Ocular Therapeutix (OCUL) is currently trading at 8,22 € with a market capitalization of 1,8 Md €. The 52-week range spans from 5,43 € to 14,33 €; the current price is 42.6% below the yearly high. Year-over-year revenue growth stands at +0.8%.
💰 Dividende
Ocular Therapeutix currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
11 analystes évaluent Ocular Therapeutix (OCUL) au consensus : Achat Fort. L'objectif de cours moyen est de 22,67 €, soit un potentiel de +175.72% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,69 € à 29,64 €.
Ocular Therapeutix : la thèse d'investissement en détail
Ocular Therapeutix (OCUL) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Strong Buy with an average price target implying roughly 175.72% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Revenue growth has slowed to just 0.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Short interest sits at 13.53% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The analyst consensus price target implies 175.72% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 13.66)
- –Positions vendeuses élevées (13.53%)
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (13.53%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Ocular Therapeutix?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
